Anti-Human MS4A1 Therapeutic Antibody (hu8E4)
Hu8E4 is a humanized anti-CD20 antibody which was generated by complementarity-determining region grafting method. Hu8E4 was as effective as rituximab in mediating antibody-dependent cellular cytotoxicity and inducing apoptosis in B-lymphoma cells, but it exhibited much more potent complement-dependent cytotoxicity than rituximab. Immunotherapeutic studies showed that hu8E4 was significantly more effective than rituximab in prolonging the survival of severe combined immunodeficient mice bearing human B-cell lymphomas, suggesting that it might be a promising therapeutic agent for B-cell lymphomas.
| Supplier | Creative Biolabs |
|---|---|
| Product # | TAB-1672CL |
| Pricing | Inquiry |
| Type | Humanized antibody |
| Applications | Inhib, CDC, ADCC, Apop, FuncS |
| Host | Human |
| Target | CD20 |